



## **Advancing Care in Multiple Myeloma:** **A New Clinical Research Study**

A Study to Investigate the Efficacy, Safety, and Tolerability of An Investigational Study Drug (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving BCMA×CD3–Directed Bispecific Antibody Therapy

### **About the MMyrelis Clinical Research Study**

The MMyrelis clinical research study is a phase 3, unblinded study, evaluating whether an investigational study drug can help prevent infections in adults with Multiple Myeloma (MM) who are currently treated with teclistamab.

The investigational study drug is an IVIG (Immune Globulin Infusion (Human) 10%), replacement therapy that has been approved globally to treat autoimmune disorders, Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Participants who agree to consent, enroll, and undergo the screening process will be administered an infusion once every 3 or 4 weeks, depending on the dosing schedule chosen between the participant and the study doctor.

This study will take up to 14 months and may require the participant to attend roughly 18 study visits.

Eligible patients must:



Be 18 years  
old or older



Have been  
diagnosed  
with MM



Have recently  
started or be about  
to start treatment for  
MM with teclistamab




Continue treating  
their MM with  
teclistamab for at  
least 12 months

Other criteria must also be met to participate.

Study-related procedures and drugs will be provided to qualified participants at no cost. This may include study-related travel expenses based on regional regulatory approvals.

For more information regarding the MMyrelis clinical research study, please visit [clinicaltrials.gov](https://clinicaltrials.gov), the study website [www.mmyrelisstudy.com/en-us/hcpf](https://www.mmyrelisstudy.com/en-us/hcpf), or reach out to me directly.

If you are interested in sharing information with a patient that you feel may be eligible, please share the study video using the QR Code below or the study website.



[www.mmyrelisstudy.com/en-us/hcpf](https://www.mmyrelisstudy.com/en-us/hcpf)



Name of contact person at study site



Telephone:



Email:

